openPR Logo
Press release

Curetis AG Signs Distribution Deal in Middle East with ATC

09-11-2012 03:36 PM CET | Health & Medicine

Press release from: Curetis AG

/ PR Agency: akampion
- Kuwait Ministry of Health clears Unyvero™ Solution for clinical evaluation -

Holzgerlingen, Germany, July 18, 2012 -- Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced that it has signed an exclusive distribution deal for its Unyvero™ solution with Advanced Technology Company K.S.C. (ATC). ATC will become the exclusive distributor of the Unyvero Solution including consumables for the six Gulf Cooperation Council (GCC) countries and the Lebanon.

Placement of instruments will start in the third quarter this year. A clinical evaluation project of the Unyvero™ Solution has been approved by the Kuwait Ministry of Health and will take place at leading clinical sites in the country. Curetis, ATC and the clinical investigators will cooperate closely during this phase, and are planning to publish evaluation data in 2013 at a renowned international medical conference.

“At present, no other region in the world has such a rapidly growing demand for improved diagnostics of infectious diseases. At the same time, there is a need to realign and modernize local health-care systems in the Middle East,” said Oliver Schacht, CEO of Curetis AG. “As an example, there is a rising prevalence of antimicrobial resistance, and only recently the World Health Organization and the GCC governments have started a joint effort to address the problem. With ATC, which is led by former executives of Beckman Coulter, Organon Teknika and Biomerieux, we have found a very experienced IVD distributor with a strong presence in this exciting market.”

“Curetis provides a unique, very elegant, efficient and easy to use solution for a major unmet medical need in the region,” said Ahmad Jeradi, VP Strategy Business Development / M&A International Operations of ATC. “We therefore expect a significant clinical benefit and commercial growth potential for the Unyvero system over the next years, and are very happy to be among the first distributors who offer it internationally.”

###

About the Unyvero™ System
The CE-marked Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.
The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.
Thereby, clinically relevant information is available within about four hours to support an informed therapy decision as early as possible.
The first CE-marked Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. Cartridges for further applications, e.g. for surgical site infections, blood stream infections and tuberculosis, are in preparation.

About Advanced Technology Company K.S.C.
Founded in 1981, ATC has rapidly grown to become one of the Middle East’s market leaders in Total Medical Systems Solutions and Healthcare Services. ATC designs and builds hospitals and healthcare institutions, and supplies a large spectrum of medical devices and healthcare products to the market, complemented by state-of the art after sales services. The company has been listed on the Kuwait Stock Exchange as ATC in 2007. With 530 employees and 15 million Dinars (approx. US$ 53 million) in paid-in capital ATC reported totals assets of USD 300 million; revenues from yearly sales and services amount to USD 240 million.

Advanced Technology Company
Tel.: +965-22247-262
Fax: +965-25711-761
www.atc.com.kw
Email: Ajeradi(at)atc.com.kw

About Curetis AG
Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million). The company is based in Holzgerlingen near Stuttgart, Germany. In 2011, Curetis signed a collaboration agreement with Sanofi Pasteur for the potential use of the Unyvero™ platform in a future global clinical trial.

Media Inquiries:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(at)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Curetis AG
Oliver Schacht, CEO
Max-Eyth-Str. 42
71088 Holzgerlingen
Germany
Tel. +49 (0) 7031 49195-10
pr(at)curetis.com
www.curetis.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Curetis AG Signs Distribution Deal in Middle East with ATC here

News-ID: 229529 • Views: 1373

More Releases from Curetis AG

Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyv …
− Curetis adds six new trial sites, significantly expanding U.S. clinical trial network for ongoing FDA study Holzgerlingen, Germany, May 14, 2014 -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that Robin Patel, M.D., Professor of Medicine and Microbiology at the Mayo Clinic in Rochester, Minn., has been named Lead Principal Investigator of the company’s Unyvero™ LRT Application FDA trial. The lower respiratory tract (LRT) application is
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
- Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples - Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more
Curetis and Scholz Collaborate to Industrialize and Scale-Up Production of Unyve …
- German family firm ‘Scholz-HTIK – High Tech in Kunststoff’ has been selected by Curetis based on systematic benchmarking process - Holzgerlingen (Germany), December 4, 2012 -- Curetis AG today announced a strategic supply chain partnership with German family business Horst Scholz GmbH + Co. KG for the production of high-quality plastics parts for its Unyvero™ Cartridge. Under the agreement, Curetis will invest more than € 2 million in multi-cavity tools for
Curetis Completes Enrollment for its EU Trial As Planned
- Prospective multi-center trial enrolls 800 patient samples in 7 months - Holzgerlingen (Germany), October 9, 2012 -- Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal. The trial will compare the

All 5 Releases


More Releases for Unyvero

Mayo Clinic’s Dr. Robin Patel Named Principal Investigator for Curetis’ Unyv …
− Curetis adds six new trial sites, significantly expanding U.S. clinical trial network for ongoing FDA study Holzgerlingen, Germany, May 14, 2014 -- Curetis AG, a developer of next-level molecular diagnostic solutions, today announced that Robin Patel, M.D., Professor of Medicine and Microbiology at the Mayo Clinic in Rochester, Minn., has been named Lead Principal Investigator of the company’s Unyvero™ LRT Application FDA trial. The lower respiratory tract (LRT) application is
Curetis AG Initiates Clinical Trial in the U.S. Towards FDA Clearance
- Prospective Multi-Center Trial to Enroll Over 2,000 Clinical Samples - Holzgerlingen, Germany, December 6, 2012 -- Curetis AG today announced the start of a clinical trial of its Unyvero™ System and the corresponding LRT (lower respiratory tract) application in the U.S. The company expects enrollment completion within the next 12-15 months, followed by a 510(k) submission to the FDA in 2014. The prospective, multicenter trial will include samples collected from more
Curetis Completes Enrollment for its EU Trial As Planned
- Prospective multi-center trial enrolls 800 patient samples in 7 months - Holzgerlingen (Germany), October 9, 2012 -- Curetis AG today announced it has completed enrollment for the European clinical trial of its Unyvero™ Pneumonia Application on schedule. More than 800 patient samples were collected until September 30, 2012. Data analysis will be completed in early 2013. Subsequently, results will be published in a major, peer-reviewed journal. The trial will compare the
Curetis AG Signs Up BioLine LLC as Exclusive Distribution Partner for Russia
- Partners to start registration process and market launch in Russia - Holzgerlingen, Germany, September 27, 2012 -- Curetis AG today announced that it has signed up BioLine LLC as an exclusive distribution partner for Russia, Ukraine, Kazakhstan and Belorus. BioLine is a major player in these markets and distributor for global companies such as Becton Dickinson, Leica Microsystems and many others. BioLine is preparing the registration of the Unyvero™ Solution and
Curetis AG Chooses Mediphos as Exclusive Distribution Partner for the Netherland …
- Partners prepare market launch and clinical evaluation project - Holzgerlingen, Germany, September 26, 2012 -- Curetis AG today announced that Curetis and Mediphos have closed an exclusive distribution agreement for the Netherlands. Mediphos is an experienced independent distributor with a clear focus on molecular diagnostics and an emphasis on microbiology-based applications. Under the agreement, both companies will prepare the market roll-out of Curetis´ Unyvero™ Solution and the Unyvero™ P50 Pneumonia
Curetis and Heraeus Medical Collaborate on the Development of New Unyvero™ Dia …
- Joint development of cartridge for orthopaedics, wound and surgery infections - Holzgerlingen and Wehrheim (Germany), September 20, 2012 -- Curetis AG and Heraeus Medical GmbH have signed a collaboration agreement to jointly develop a novel Unyvero™ cartridge for the detection of pathogens and antibiotic resistances in implant & tissue infections (ITI). One key application area will be in orthopaedics, e.g. to diagnose infections after knee and hip replacement surgeries. Under